Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
American Journal of Infection Control|July 23, 2021
Universal symptom monitoring to address presenteeism in healthcare workersAmos Lichtman, Ethan Greenblatt, Jason Malenfant, et al.Journal of Medical Virology|April 13, 2026
Effectiveness of Remdesivir on All-Cause In-Hospital Mortality in Patients With Chronic Respiratory Comorbidities Who Are Hospitalized With COVID-19 in the United StatesVeronika Müller, Martin Kolditz, Valentina Shvachko, et al.Journal of Global Health|December 3, 2016
Ebola research funding: a systematic analysis, 1997-2015Joseph Ra Fitchett, Amos Lichtman, Damilola T Soyode, et al.Antiviral Research|December 31, 2025
SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19Lauren Rodriguez, Yu Hu, Jiani Li, et al.Clinical Pharmacology and Therapeutics|January 31, 2025
Clinical Evaluation of Drug-Drug Interactions with Obeldesivir, an Orally Administered Antiviral AgentChi-Chi Peng, Rita Humeniuk, Anuja Raut, et al.BMC Nephrology|July 27, 2016
The Rivas Cohort Study: design and baseline characteristics of a Nicaraguan cohortKailey Minnings, Madeline Fiore, Martha Mosco, et al.Clinical Pharmacology and Therapeutics|June 28, 2024
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy ParticipantsOlena Anoshchenko, Mazin Abdelghany, Amos Lichtman, et al.Journal of Hepatology|April 12, 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trialHeiner Wedemeyer, Soo Aleman, Antje Blank, et al.The Lancet. Infectious Diseases|July 17, 2025
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled studyOnyema Ogbuagu, Jason D Goldman, Robert L Gottlieb, et al.Pageof 1